|SEND TO PRINTER|
Assay Tutorials : Dec 1, 2009 ( )
Investigating Cell Invasion and Migration
Beyond Endpoint Analysis: Real-Time Monitoring Enables Greater Insight into Cellular Behavior
For researchers performing invasion and migration assays, the CIM-Plate 16 used with the xCELLigence Real-Time Cell Analyzer (RTCA) DP instrument from Roche Applied Science, a business area of Roche Diagnostics, offers a means to monitor cellular responses in real time, without exogenous labels, through impedance-based technology. The CIM-Plate 16 provides a kinetic cell-response profile throughout an experiment, detailing the onset and rate of invasion and migration. This information can help researchers understand processes that current endpoint experiments are unable to address.
The study of cell invasion and migration is of great importance to enable a better understanding of underlying biological and molecular mechanisms. The new CIM-Plate 16 device detects real-time invasion and migration of cells without the use of labels.
Cell invasion is the intrusion on and destruction of adjacent tissues, particularly with respect to cancer cells. Cell migration is the movement of cells from one area to another, generally in response to chemical signal; it is important in diverse physiological and pathological processes, including embryonic development, cell differentiation, wound healing, immune response, inflammation, and notably, cancer metastasis.
Conventional methodologies for migration detection are endpoint and label-based assays. One of the more commonly used methods is the Boyden chamber (also called trans-well migration assay), whereby cells placed in inserts are allowed to invade and migrate through an artificial microporous membrane into lower chambers containing a given chemoattractant.
There are drawbacks to this approach. The migrated cells (typically attached on the reverse side of the membrane) must be stained with chemical dyes or labeled with fluorescent molecules. In most cases, the membrane is removed from the insert, and then the stained or labeled cells are counted manually using a microscope or evaluated using a spectrometer.
This labor-intensive process limits throughput and, as a result of labeling the cells, may alter gene-expression profiles and lead to intra-assay variability because of differences in labeling efficiency. Additionally, cell counting by means of microscopy may not be accurate, often resulting in inconsistent and irreproducible migration data.
In contrast to conventional methods, the Roche xCELLigence RTCA DP Instrument provides kinetic information about cell migration by dynamically recording the entire cell migration and invasion process in real time without labeling cells, considerably improving invasion and migration assay quality.
The RTCA DP Instrument uses the CIM (cellular invasion/migration)-Plate 16, which features microelectronic sensors integrated onto the underside of the microporous polyethylene terephthalate membrane of a Boyden-like chamber (Figure 1).
As cells migrate from the upper chamber through the membrane into the bottom chamber in response to chemoattractant, they contact and adhere to the electronic sensors on the underside of the membrane, resulting in an increase in impedance. The impedance increase correlates to increasing numbers of migrated cells on the underside of the membrane, and cell-index values reflecting impedance changes are automatically and continuously recorded by the RTCA DP Instrument (Figures 2 and 3). Therefore, cell-migration activity can be monitored via the cell-index profile.
The following is a basic migration assay protocol used on the RTCA DP Instrument with fetal bovine serum (FBS) as chemoattractant. The protocol is optimized for two cancer cell lines: a human fibrosarcoma cell line, HT1080, and a human breast adenocarcinoma cell line, MDA-MB-231. Assay conditions may require further optimization if different types of cell lines or chemoattractants are used.
1. Cells should be grown in serum-free medium for 4–24 hours.
We analyzed different densities of MDA-MB-231 cells in the absence or presence of 10% FBS in the bottom chamber (Figure 2). Cell migration kinetics were recorded by the RTCA DP Instrument for approximately 24 hours. Migration kinetics were distinct and easily detected by automated real-time monitoring. The low- to high-seeding densities were quantitatively monitored and reflected by the cell-index values, and were correlated with a manual cell count determined at the end of the assay by fixing and staining the cells on the membrane of the top chamber (data not shown).
We monitored migration and invasion kinetics—in the absence and presence of Matrigel, respectively—in response to 10% FBS (Figure 3). In the absence of serum, we observed little to no migration. As indicated by the cell-index profiles, cell invasion and migration was affected in a dose-dependent manner by the concentration of Matrigel. The rate and onset of invasion were readily quantified by real-time monitoring while concurrently assessing migration. The delay of cell-index signal (Figure 3) correlates with the time required for the cells to invade through the Matrigel and was dependent on Matrigel concentration.
The cancerous cells shown have varying migratory and invasive behaviors, specific to chemoattractant stimuli or Matrigel concentration. The new CIM-Plate 16 for the RTCA DP instrument is a versatile device for the analysis of invasion and migration, and is the only platform capable of quantitatively measuring the invasive and migratory behavior of cells in real time without exogenous labels.
This enables the identification of migratory and invasive time points, which will help increase throughput by shortening assay time, minimize the number of endpoint assays, and help determine optimal time points for inhibitor studies. Moreover, analysis using the xCELLigence System reduces hands-on cell manipulation steps, leading to more physiologically relevant results.
Christopher Bird, Ph.D., is a global management trainee, Kairat Madin, Ph.D., is manager R&D system project leader, and Shelli Kirstein, Ph.D. (firstname.lastname@example.org), is field segment marketing manager, xCELLigence, at Roche Diagnostics. The CIM-Plate 16 will launch in Q4 2009. More information about the xCELLigence System is available at www.xcelligence.roche.com. For life science research only. Not for use in diagnostic procedures. xCELLigence is a trademark of Roche. Matrigel is a trademark of BD. CIM-Plate is a registered trademark of ACEA Biosciences.
© 2012 Genetic Engineering & Biotechnology News, All Rights Reserved